Natera, Inc. (NASDAQ:NTRA) Shares Sold by Fifth Third Bancorp

Fifth Third Bancorp lowered its holdings in Natera, Inc. (NASDAQ:NTRA) by 81.1% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,064 shares of the medical research company’s stock after selling 4,565 shares during the period. Fifth Third Bancorp’s holdings in Natera were worth $150,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the business. LRI Investments LLC purchased a new stake in Natera during the 4th quarter worth approximately $29,000. Blue Trust Inc. increased its holdings in Natera by 223.7% during the 4th quarter. Blue Trust Inc. now owns 301 shares of the medical research company’s stock worth $48,000 after purchasing an additional 208 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in Natera by 372.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock worth $52,000 after purchasing an additional 261 shares during the last quarter. Principal Securities Inc. increased its holdings in Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after purchasing an additional 59 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC increased its holdings in Natera by 1,328.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company’s stock worth $57,000 after purchasing an additional 332 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on NTRA shares. Canaccord Genuity Group restated a “buy” rating and set a $180.00 price objective on shares of Natera in a report on Wednesday, February 26th. Barclays lifted their price objective on shares of Natera from $160.00 to $190.00 and gave the stock an “overweight” rating in a report on Friday, May 9th. Wall Street Zen cut shares of Natera from a “hold” rating to a “sell” rating in a report on Saturday, May 17th. UBS Group lifted their price target on shares of Natera from $211.00 to $218.00 and gave the company a “buy” rating in a report on Friday, May 9th. Finally, Robert W. Baird boosted their price objective on shares of Natera from $183.00 to $188.00 and gave the company an “outperform” rating in a research report on Friday, February 28th. One analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $184.63.

Insider Activity at Natera

In related news, insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $140.48, for a total transaction of $421,440.00. Following the transaction, the insider now directly owns 141,782 shares of the company’s stock, valued at $19,917,535.36. The trade was a 2.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gail Boxer Marcus sold 4,000 shares of the company’s stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $164.44, for a total transaction of $657,760.00. Following the completion of the sale, the director now directly owns 5,704 shares of the company’s stock, valued at $937,965.76. The trade was a 41.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 59,755 shares of company stock worth $8,898,589 over the last quarter. 7.60% of the stock is currently owned by company insiders.

Natera Stock Performance

NASDAQ:NTRA opened at $170.98 on Friday. The stock has a market cap of $23.35 billion, a price-to-earnings ratio of -116.31 and a beta of 1.74. Natera, Inc. has a 1 year low of $92.14 and a 1 year high of $183.00. The business has a fifty day moving average of $156.53 and a 200-day moving average of $158.62.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.09. The business had revenue of $501.83 million during the quarter, compared to the consensus estimate of $446.68 million. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. The company’s quarterly revenue was up 36.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.56) earnings per share. On average, equities research analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.